Abstract Body

Background: Despite major successes in antiretroviral therapies against HIV-1, discovery of new drugs is necessary to enhance treatment options and counter resistance. BIT225 is an acylguanidine based compound that is reported to inhibit HIV-1 replication in myeloid cells by blocking the viroporin function of Vpu. Here, we test the anti-HIV-1 activity of a novel acylguanidine compound SM111.

Methods: We used a GFP-reporter T cell assay to test the ability of SM111 to inhibit replication of WT NL4.3, NL4.3ΔVpu (lacking vpu), and recombinant NL4.3 strains encoding major resistance mutations in pol for inhibitors of Reverse Transcriptase (RTI), Protease (PI) and Integrase (INI). Viral spread was monitored by flow cytometry over a 7-day period. Cytotoxicity was evaluated using ViaCount (Millipore). WT NL4.3 was also passaged in the presence of SM111. Three independent drug-resistant strains were isolated, sequenced and assessed for their sensitivity to SM111. Vpu-mediated downregulation of CD4 and tetherin was monitored by flow cytometry.

Results: SM111 inhibited NL4.3 in a dose-dependent manner between 10µM and 100µM, and was non-toxic at 100µM concentration (viability >90%, similar to media control). Infected cells (%GFP+) were reduced >98% at 100µM (56.7% [55.3-57.7] in absence vs. 0.89 % [0.76-0.99] in presence of SM111) at day 7. Similar activity was observed against RTI, PI and INI resistance strains (>95% reduction in all cases). All SM111-resistant viruses encoded mutations in the transmembrane of Vpu, including a 5AA deletion (clone A), a stop codon at highly conserved W22 (clone C) or a substitution (I17R) (clone H), which impaired Vpu-mediated downregulation of CD4 and Tetherin. Notably, SM111 was only partially active against NL4.3ΔVpu (46.5% [44-48.2] in absence vs. 22.4% [20.1-25.7] in presence of drug); and growth of resistant strains was inhibited to various degrees by SM111 (92%; 54%; and 16% reduction for clone A; C; and H respectively).

Conclusions: SM111 is a novel compound that inhibits replication of WT as well as RTI, PI and INI resistant HIV-1 strains. Passaging of NL4.3 with SM111 selected major mutations in Vpu. However, these mutants and a ΔVpu strain remained partially sensitive to the drug, suggesting that Vpu may not be SM111’s primary target. Our results indicate that SM111’s mechanism of action is unique from current antiretroviral drugs, but more studies are necessary to explore this promising prototype.
Funded by CIHR & the Michael Smith Foundation for Health Research

viewer?TAG_ACTION=SECURE_FILE_DOWNLOAD&V
SM111 chemical structure